FrancophonIA/ELRC3.0 huggingface dataset:
English: The primary objective was to demonstrate the noninferiority of T12(b.i.d.
Croatian: Primarni cilj bio je pokazati neinferiornosti T12(b.i.d.)/PR u odnosu na T12(q8h)/PR.
English: Co-administration with phenobarbital is contraindicated.
Croatian: Istodobna primjena s fenobarbitalom je kontraindicirana.
English: The study was designed to compare SVR rates in patients with undetectable HCV RNA ( target not detected) at weeks 4 and 12 who were treated with INCIVO for 12 weeks in combination with peginterferon alfa-2a and ribavirin for either 24 weeks (T12/PR24 regimen) or 48 weeks (T12/PR48 regimen).
Croatian: Ispitivanje je bilo ustrojeno tako da su se uspoređivale stope SVR u bolesnika s nemjerljivim HCV RNK (cilj nije izmjeren) u 4. i 12. tjednu liječenih INCIVOM tijekom 12 tjedana, u kombinaciji s peginterferonom alfa-2a i ribavirinom koji su se davali 24 tjedana (režim T12/PR24) ili 48 tjedana (režim T12/PR48).
English: HCV/Human immunodeficiency virus type (HIV)-1 co-infection HCV/HIV-1 co-infected patients should be treated in the same way as HCV mono-infected patients.
Croatian: Bolesnici koji su istodobno inficirani s HCV-om i HIV-om-1 moraju se liječiti na isti način kao i bolesnici s HCV monoinfekcijom.
English: Table 15 shows the response rates for the T12/PR48 and the Pbo/PR48 arms.
Croatian: Tablica 15 prikazuje stope odgovora za skupine T12/PR48 i Pbo/PR48.
English: Potent CYP3A inducers, such as carbamazepine, phenytoin and phenobarbital, are contraindicated
Croatian: Kontraindicirani su jaki induktori CYP3A, kao što su karbamazepin, fenitoin i fenobarbital (vidjeti dio 4.3).
English: No fibrosis, minimal fibrosis, or portal fibrosis
Croatian: Bez fibroze, minimalna fibroza ili
English: All patients received 12 weeks of treatment with INCIVO in combination with peginterferon alfa-2a and ribavirin.
Croatian: Svi bolesnici su bili liječeni 12 tjedana INCIVOM u kombinaciji s peginterferonom alfa-2a i ribavirinom.
English: 21.6% of patients receiving INCIVO combination treatment required ribavirin dose reduction for anaemia compared to 9.4% of patients receiving peginterferon alfa and ribavirin alone.
Croatian: Smanjenje doze ribavirina zbog anemije bilo je potrebno u 21,6% bolesnika liječenih kombiniranom terapijom INCIVOM, u odnosu na 9,4% bolesnika koji su primali samo peginterferon alfa i ribavirin.
English: INCIVO must not be restarted if discontinued by your doctor.
Croatian: Ne smijete ponovno početi uzimati INCIVO ako Vam je liječnik prekinuo primjenu
English: During the INCIVO/placebo treatment phase, the most frequently reported ADRs of at least Grade 3 in the INCIVO group (incidence ≥ 1.0%) were anaemia, rash, thrombocytopenia, lymphopenia,
Croatian: Tijekom faze liječenja INCIVOM/placebom, najčešće zabilježene nuspojave najmanje 3. stupnja u skupini koja je primala INCIVO (incidencija ≥ 1,0%) bile su anemija, osip, trombocitopenija, limfopenija, svrbež i mučnina.
English: Eye disorders uncommon retinopathy
Croatian: Poremećaji oka manje često retinopatija
English: hypromellose acetate succinate, calcium hydrogen phosphate (anhydrous), microcrystalline cellulose, silica colloidal anhydrous, sodium lauryl sulphate, croscarmellose sodium, sodium polyvinyl alcohol, macrogol, talc, titanium dioxide (E171), iron oxide yellow (E172)
Croatian: Hipromeloza acetat sukcinat, bezvodni kalcijev hidrogenfosfat, mikrokristalična celuloza, bezvodni silicijev dioksid koloidni, natrijev laurilsulfat, umrežena karmelozanatrij, natrijev
English: Gastrointestinal disorders very common nausea, diarrhoea, vomiting, haemorrhoids, proctalgia common anal pruritus, rectal haemorrhage, anal fissure uncommon proctitis, pancreatitis
Croatian: Poremećaji probavnog sustava vrlo često mučnina, proljev, povraćanje, hemoroidi, proktalgija često analni svrbež, rektalno krvarenje, analna fisura manje često proktitis, pankreatitis
English: INCIVO must not be administered as monotherapy and must only be prescribed in combination with both peginterferon alfa and ribavirin.
Croatian: INCIVO se ne smije primjenjivati kao monoterapija i mora se propisivati samo u kombinaciji s peginterferonom alfa i ribavirinom.
English: Permanent and immediate discontinuation of INCIVO, peginterferon alfa, and ribavirin.
Croatian: Trajni i neodložni prestanak primjene INCIVA, peginterferona alfa i ribavirina.
English: In Phase 3 studies, a sensitive real-time PCR assay with a limit of quantification of 25 IU/ml and a limit of detection of 10-15 IU/ml was used to determine whether HCV RNA levels were undetectable (target not detected) (see section 5.1).
Croatian: Za provjeru jesu li koncentracije HCV RNK nemjerljive (cilj nije izmjeren), u fazi III ispitivanja, koristio se osjetljivi test lančane reakcije polimerazom (PCR) u stvarnom vremenu s granicom kvantifikacije od 25 IU/ml i granicom mjerljivosti od 10-15 IU/ml (vidjeti dio 5.1).
English: dexamethasone if taken by mouth or through to treat asthma or to treat inflammatory and autoimmune conditions (corticosteroids)
Croatian: budezonid, inhalacijski flutikazon ili flutikazon za primjenu u nos, deksametazon ako se uzima kroz usta ili prima injekcijom za liječenje astme ili za liječenje upalnih i autoimunih stanja (kortikosterodi)
English: If you have any questions about your medicines, please ask your doctor or pharmacist.
Croatian: Ako imate pitanja o lijekovima koje uzimate, molimo obratite se liječniku ili ljekarniku.
English: Use INCIVO with caution in patients with: - a history of acquired QT prolongation; - clinically relevant bradycardia (persistent heart rate < 50 bpm); - a history of heart failure with reduced left-ventricular ejection fraction; - a requirement for medicinal products known to prolong the QT interval but the metabolism of which is not mainly CYP3A4 dependent (e.g. methadone, see section 4.5).
Croatian: INCIVO treba primjenjivati s oprezom u bolesnika: - koji u povijesti bolesti imaju stečeno produljenje QT intervala; - s klinički značajnom bradikardijom (frekvencija srca trajno < 50 otkucaja u minuti); - koji u povijesti bolesti imaju srčano zatajenje sa smanjenom ejekcijskom frakcijom lijevog ventrikula;
English: There are limited clinical data on the use of INCIVO in HCV patients aged ≥ 65 years.
Croatian: Postoje samo ograničeni klinički podaci o primjeni INCIVA u bolesnika s HCV-om starosti
English: If the missed dose is noticed more than 6 hours after the time INCIVO should be taken, the missed dose should be skipped and the patient should resume the normal dosing schedule.
Croatian: Ako se propuštena doza primjeti nakon više od 6 sati od vremena kad je bolesnik trebao uzeti INCIVO, propuštenu dozu treba preskočiti te nastaviti uzimati lijek prema uobičajenom rasporedu doziranja.
English: Study C211 was a randomised, open-label, Phase 3 study conducted in treatment-naïve patients who were randomised to one of two treatment groups: INCIVO 750 mg every 8 hours [T12(q8h)/PR] or INCIVO 1,125 mg twice daily [T12(b.i.d.
Croatian: Ispitivanje C211 bilo je randomizirano, otvoreno, faze III, provedeno u bolesnika koji prethodno nisu bili liječeni i koji su bili randomizirani u jednu od dviju skupina liječenja: INCIVO 750 mg svakih 8 sati [T12(q8h)/PR] ili INCIVO 1125 mg dva puta na dan [T12(b.i.d.)/PR] u kombinaciji s peginterferonom alfa-2a i ribavirinom.
English: Study C216 was a randomised, double-blind, placebo-controlled, Phase 3 study conducted in patients who did not achieve SVR with prior treatment with peginterferon alfa-2a and ribavirin or peginterferon alfa-2b and ribavirin.
Croatian: Ispitivanje C216 bilo je randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje, faze III, provedeno u bolesnika koji nisu postigli SVR uz prethodno liječenje peginterferonom alfa-2a i ribavirinom ili peginterferonom alfa-2b i ribavirinom.
English: On-treatment virologic failure was defined as meeting a virologic stopping rule and/or having viral breakthrough.
Croatian: Virološki neuspjeh tijekom liječenja bio je definiran kao dostizanje viroloških pravila za prekid i/ili doživljavanje virološkog proboja.
English: In placebo-controlled Phase 2 and 3 trials, the overall incidence and severity of rash increased when INCIVO was co-administered with peginterferon alfa and ribavirin.
Croatian: U fazi II i III placebom kontroliranih ispitivanja ukupna incidencija i težina osipa povećale su se kad se INCIVO primjenjivao istodobno s peginterferonom alfa i ribavirinom.
English: Treatment with INCIVO must be initiated in combination with peginterferon alfa and ribavirin and administered for 12 weeks with an additional 36 weeks of peginterferon alfa and ribavirin alone for a total treatment duration of 48 weeks.
Croatian: Liječenje INCIVOM se mora započeti u kombinaciji s peginterferonom alfa i ribavirinom i primjenjivati tijekom 12 tjedana uz dodatnih 36 tjedana liječenja samo peginterferonom alfa i ribavirinom do ukupnog trajanja liječenja od 48 tjedana.
English: Naïve patients treated with either peginterferon alfa-2a/ribavirin (n = 80) or peginterferon alfa-2b/ribavirin (n = 81) in combination with INCIVO, in an open label study, had comparable SVR rates.
Croatian: U ispitivanju otvorenog tipa, bolesnici koji prethodno nisu bili liječeni a primali su ili peginterferon alfa-2a/ribavirin (n = 80) ili peginterferon alfa-2b/ribavirin (n = 81) u kombinaciji s lijekom INCIVO, imali su usporedive stope SVR.
English: It is not recommended to co-administer darunavir/ritonavir and telaprevir (see section 4.4).
Croatian: Ne preporučuje se istodobno primjenjivati darunavir/ritonavir s telaprevirom (vidjeti dio 4.4).
English: On-treatment virologic failure was defined as meeting a virologic stopping rule or having viral breakthrough.
Croatian: Virološki neuspjeh tijekom liječenja bio je definiran kao dostizanje virološkog pravila za prekid ili doživljavanje virološkog proboja.
English: versus 750 mg every 8 hours (q8h) were 1.08 (1.02; 1.13) for AUC24,ss, 0.878 (0.827; 0.930) for Ctrough,ss, and 1.18 (1.12;1.24) for Cmax,ss.
Croatian: Na temelju populacijskog farmakokinetičkog modela izloženosti telapreviru u stanju dinamičke ravnoteže, geometrijska srednja vrijednost omjera najmanjih kvadrata (90% CI) za 1125 mg dva puta na dan (b.i.d.) naspram 750 mg svakih 8 sati bila je 1,08 (1,02; 1,13) za AUC24,ss, 0,878 (0,827; 0,930) za Cnajniža,ss, i 1,18 (1,12;1,24) za Cmax,ss.
English: Female patients of childbearing age and their male partners A hormonal contraceptive (‘the pill') may not be reliable during the treatment with INCIVO.
Croatian: Hormonska kontracepcija (”pilula”) ne mora biti pouzdana metoda za vrijeme liječenja INCIVOM.
English: Study 106 was a randomised, double-blind, placebo-controlled, Phase 2 study that enrolled patients who had failed prior treatment with peginterferon alfa-2a and ribavirin or peginterferon alfa-2b and ribavirin.
Croatian: Ispitivanje 106 bilo je randomizirano, dvostruko slijepo, placebom kontrolirano ispitivanje, faze II, koje je uključilo bolesnike u kojih je prethodno liječenje peginterferonom alfa-2a i ribavirinom ili peginterferonom alfa-2b i ribavirinom bilo neuspješno.
English: The safety and efficacy of INCIVO in children aged < 18 years have not yet been established.
Croatian: < 18 godina nisu još ustanovljene.
English: Use of INCIVO in treatment of other HCV genotypes There are not sufficient clinical data to support the treatment of patients with HCV genotypes other than genotype 1.
Croatian: Ne postoji dovoljno kliničkih podataka koji bi podržali liječenje bolesnika s HCV infekcijom izazvanom drugim genotipovima HCV-a osim genotipa
English: Following the end of the INCIVO treatment, please see the ribavirin package leaflet regarding continued contraception
Croatian: Kada završite liječenje INCIVOM, molimo vas pročitajte što piše u uputi o lijeku za ribavirin o potrebama daljnjeg sprječavanja trudnoće.
English: Electrolyte disturbances (e.g., hypokalaemia, hypomagnesaemia and hypocalcaemia) should be monitored and corrected, if necessary, prior to initiation and during INCIVO therapy.
Croatian: Prije početka i za vrijeme terapije INCIVOM treba pratiti i po potrebi korigirati poremećaje elektrolita (npr. hipokalijemiju, hipomagnezijemiju i hipokalcijemiju).
English: General disorders and administration site conditions common oedema peripheral, product taste abnormal the placebo-controlled Phase 2 and Phase 3 Studies (pooled data) included 1,346 HCV-infected patients incidence rates are based on adverse event reporting rates (additionally, see Laboratory abnormalities below)
Croatian: Opći poremećaji i reakcije na periferni edem, abnormalan okus proizvoda faze II i faze III placebom kontroliranih ispitivanja (objedinjeni podaci) uključile su 1346 bolesnika zaraženih HCV
English: - Patients with undetectable hepatitis C virus ribonucleic acid (HCV RNA) (target not detected) at weeks 4 and 12 receive an additional 12 weeks of peginterferon alfa and ribavirin alone for a total treatment duration of 24 weeks.
Croatian: - Bolesnici u kojih ribonukleinska kiselina virusa hepatitisa C (HCV RNK) nije mjerljiva (cilj nije izmjeren) u 4. i 12. tjednu liječenja nastavit će primati samo peginterferon alfa i ribavirin još 12 tjedana, tako da liječenje traje ukupno 24 tjedna.
English: BOTTLE LABEL (4-bottle pack)
Croatian: NALJEPNICA NA BOČICI (pakiranje od 4 bočice)
English: to treat inflammatory arthritis (anti-gout agents) to treat certain infections (antimycobacterials) to help you sleep and/or relieve anxiety (benzodiazepines) to help you sleep and/or relieve anxiety (non-benzodiazepine sedatives)
Croatian: alprazolam, midazolam u obliku injekcije za spavanje i/ili ublažavanje tjeskobe (benzodiazepini) za spavanje i/ili ublažavanje tjeskobe (nebenzodiazepinski sedativi)
English: Additional methods of non-hormonal contraception should be used when hormonal contraceptives are co-administered with telaprevir.
Croatian: Kad se hormonska kontracepcija primjenjuje istodobno s telaprevirom, potrebne su dodatne nehormonske metode kontracepcije.
English: Relapse was defined as having HCV RNA ≥ 25 IU/ml during the follow-up period after previous HCV RNA < 25 IU/ml at planned end of treatment and not achieving SVR12.
Croatian: Relaps je bio definiran kao HCV RNK ≥ 25 IU/ml tijekom razdoblja praćenja nakon prethodne HCV RNK < 25 IU/ml na planiranom kraju liječenja i nepostizanje SVR12.
English: Improvement of rash occurs after INCIVO dosing completion or discontinuation; however, rashes may take several weeks to
Croatian: Nakon završetka doziranja INCIVA ili prekida njegove primjene dolazi do poboljšanja osipa, međutim, povlačenje osipa može trajati i
English: No clinical data are available regarding the treatment of pre- or peri-liver or other transplant patients with INCIVO in combination with peginterferon alfa and ribavirin.
Croatian: Ne postoje dostupni klinički podaci o liječenju bolesnika INCIVOM u kombinaciji s peginterferonom alfa i ribavirinom prije ili za vrijeme transplantacije jetre ili drugih organa.
English: Relapse was defined as having detectable plasma HCV RNA from planned end of treatment onwards after previous HCV RNA < 25 IU/ml at planned end of HCV treatment, and not achieving SVR12.
Croatian: Relaps je bio definiran kao prisutnost mjerljivog HCV RNK u plazmi od planiranog kraja liječenja nadalje nakon prethodnog HCV RNK < 25 IU/ml na planiranom kraju HCV liječenja, te nepostizanje SVR12.
English: Manufacturer Janssen-Cilag SpA, Via C. Janssen,
Croatian: Proizvođač Janssen-Cilag SpA,
English: The total dose is 6 tablets or - 2 tablets of INCIVO every 8 hours with food.
Croatian: - 2 tablete INCIVA svakih 8 sati uz hranu.
English: Table 11 shows the response rates for the recommended simultaneous start (T12/PR48) and the Pbo/PR48 arms.
Croatian: Tablica 11 pokazuje stope odgovora u skupini s preporučenim istodobnim početkom liječenja (T12/PR48) i u skupini Pbo/PR48.
English: The impact of predominant telaprevir-resistant variants at baseline is likely greatest in patients with a poor interferon response,
Croatian: Vjerojatno je utjecaj varijanti pretežno rezistentnih na telaprevir na početku liječenja najveći u bolesnika sa slabim odgovorom na interferon, kao što su bolesnici u kojih je prethodno potpuno izostao terapijski odgovor.
English: Other includes patients with detectable HCV RNA at their actual end of treatment but who did not meet the definition of on-treatment virologic failure, and patients with a missing HCV RNA assessment during planned follow-up.
Croatian: Ostalo uključuje bolesnike s mjerljivom HCV RNK na njihovom stvarnom kraju liječenja, ali koji nisu zadovoljili definiciju virološkog neuspjeha tijekom liječenja, te bolesnike bez procijenjene HCV RNK tijekom planiranog praćenja.
English: Treatment-naive patients or prior relapsers who were non-cirrhotic and achieved extended rapid virologic response (eRVR) received 12 weeks of treatment with INCIVO plus peginterferon alfa-2a and ribavirin followed by 12 weeks of treatment with peginterferon alfa-2a and ribavirin (total treatment duration of 24 weeks).
Croatian: Bolesnici koji prethodno nisu bili liječeni ili oni koji su prethodno doživjeli relaps te su bez ciroze jetre i postigli su produženi brzi virološki odgovor (eRVR, engl. extended rapid virologic response), liječeni su INCIVOM plus peginterferon alfa-2a i ribavirin tijekom12 tjedana, nakon čega je uslijedilo liječenje u trajanju od 12 tjedana s peginterferonom alfa-2a i ribavirinom (ukupno trajanje liječenja od 24 tjedna).
English: Table 1: Guidelines for discontinuation of INCIVO, Peginterferon Alfa, and Ribavirin treatment
Croatian: Tablica 1: Smjernice za prestanak liječenja INCIVOM, peginterferonom alfa i ribavirinom Lijekovi
English: In the C211 Phase 3 clinical trial, there was no difference in the type of emerging variants between patients receiving telaprevir 1,125 mg twice daily (b.i.d.)
Croatian: U fazi III C211 kliničkog ispitivanja nije bilo razlike u tipu varijanti u nastajnju između bolesnika koji su primali 1125 mg telaprevira dva puta na dan (b.i.d.) i bolesnika koji su primali 750 mg telaprevira svakih 8 sati.
English: Ribavirin can damage your unborn baby.
Croatian: Ribavirin može naškoditi vašem nerođenom djetetu, stoga je neophodno poduzeti sve mjere opreza kako ne biste zatrudnjeli za vrijeme trajanja liječenja.
English: Because INCIVO must be used in combination with peginterferon alfa and ribavirin, the contraindications and warnings applicable to those medicinal products are applicable to combination therapy.
Croatian: Budući da se INCIVO mora primjenjivati u kombinaciji s peginterferonom alfa i ribavirinom, kontraindikacije i upozorenja koja vrijede za navedene lijekove, vrijede i za kombiniranu terapiju.
English: HIV-ANTIVIRAL AGENTS: HIV-PROTEASE INHIBITORS (PIs) atazanavir/ritonavir*
Croatian: ANTIVIRUSNI LIJEKOVI PROTIV HIV-a: INHIBITORI REVERZNE TRANSKRIPTAZE efavirenz*
English: HCV RNA > 1,000 IU/ml at week 12 of treatment
Croatian: HCV RNK > 1000 IU/ml nakon 12 tjedana liječenja
English: QT interval prolongation and Torsade de Pointes have been reported with clarithromycin and erythromycin.
Croatian: Uz klaritromicin i eritromicin zabilježeni su produljenje QT intervala i torsade de pointes.
English: QT interval prolongation has been reported with telithromycin (see section 4.4).
Croatian: Produljenje QT intervala prijavljeno je s telitromicinom (vidjeti dio 4.4).
English: Co-administration of atorvastatin and telaprevir is contraindicated (see section 4.3).
Croatian: Istodobna primjena atorvastatina s telaprevirom je kontraindicirana (vidjeti dio 4.3).
English: Hepatobiliary disorders common hyperbilirubinaemia
Croatian: Poremećaji jetre i žuči često hiperbilirubinemija
English: Refer to the Summary of Product Characteristics for peginterferon alfa and ribavirin for a list of their contraindications since INCIVO must be used in combination with peginterferon alfa and ribavirin.
Croatian: Za popis kontraindikacija za peginterferon alfa i ribavirin, vidjeti odgovarajuće Sažetke opisa svojstava lijeka, budući da se INCIVO mora primjenjivati u kombinaciji s peginterferonom alfa i ribavirinom.
English: Uncommon side effects (affects less than 1 in 100 people): - increase in creatinine in your blood; - painful inflammation of the joints most commonly in the foot (gout); - damage to back of the eye (retina); - inflammation of the anus and rectum; - inflamed pancreas
Croatian: Manje česte nuspojave (javljaju se u manje od 1 na 100 osoba): - povišenje kreatinina u krvi; - bolna upala zglobova, najčešće zglobova stopala (giht);
English: Plasma concentrations of telaprevir can be reduced by concomitant use of the herbal preparation St John's wort (Hypericum perforatum).
Croatian: Istodobna primjena biljnih pripravaka gospine trave (Hypericum perforatum) može smanjiti koncentracije telaprevira u plazmi.
English: 5.8% of patients discontinued INCIVO alone due to rash events and 2.6% of patients discontinued INCIVO combination treatment for rash events compared to none of those receiving peginterferon
Croatian: Zbog pojave osipa 5,8% bolesnika prekinulo je liječenje INCIVOM, a 2,6% bolesnika prekinulo je kombinirano liječenje INCIVOM, dok prekida zbog pojave osipa nije bilo ubolesnika koji su primali peginterferon alfa i ribavirin.
English: Upon completion of INCIVO, doses of tacrolimus or cyclosporine A need to be increased, and the dosing interval for tacrolimus will need to be reduced.
Croatian: Nakon završetka liječenja INCIVOM, potrebno je doze takrolimusa ili ciklosporina
English: For specific dosage instructions for peginterferon alfa and ribavirin, the Summary of Product Characteristics for these medicinal products should be consulted.
Croatian: Za posebne upute vezane uz doziranje peginterferona alfa i ribavirina potrebno je pogledati Sažetak opisa svojstava lijeka za te lijekove.
English: At baseline, 3 (8%) patients had bridging fibrosis and 2 (5%) patients had cirrhosis in the T12/PR48 arm.
Croatian: U skupini T12/PR48, 3 (8%) bolesnika na početku ispitivanja je imalo premoštavajuću fibrozu, a 2 (5%) bolesnika imalo je cirozu.
English: Study HPC3006 was an open-label, Phase 3b study in treatment- naïve and treatment-experienced chronic genotype 1 HCV- infected patients who were first time liver transplant recipients and were on a stable regimen of the immunosuppressants tacrolimus or cyclosporine A. No patients had cirrhosis of the liver graft.
Croatian: Ispitivanje HPC3006 bilo je otvoreno ispitivanje faze 3b, u bolesnika s kroničnom infekcijom HCV genotipa 1 koji prethodno nisu bili liječeni i u prethodno liječenih bolesnika kojima je prvi put transplantirana jetra, te su bili na stabilnom režimu liječenja s imunosupresivima takrolimusom ili ciklosporinom A.
English: Patients who had undetectable HCV RNA (target not detected) at weeks 4 and 12 received 24 weeks of peginterferon alfa-2a and ribavirin treatment, and patients who did not have undetectable HCV RNA (target not detected) at week 4 and week 12 received 48 weeks of peginterferon alfa-2a and ribavirin treatment.
Croatian: Bolesnici s nemjerljivim HCV RNK (cilj nije izmjeren) u 4. i 12. tjednu primali su peginterferon alfa-2a i ribavirin 24 tjedna, a bolesnici s mjerljivim HCV RNK (cilj nije izmjeren) u 4. i 12. tjednu liječeni su peginterferonom alfa-2a i ribavirinom 48 tjedana.
English: an herbal product to relieve anxiety to lower cholesterol levels (HMG CoA reductase inhibitors)
Croatian: biljni pripravak za ublažavanje tjeskobe atorvastatin, lovastatin, simvastatin za sniženje vrijednosti kolesterola (inhibitori HMG CoA reduktaze)
English: Table 17: Treatment outcome in genotype 1 HCV-infected liver transplant recipients (Study HPC3006)
Croatian: Tablica 17: Ishod liječenja kod bolesnika s infekcijom HCV-om genotipa 1 s transplantiranom
English: Baseline liver fibrosis No fibrosis or minimal fibrosis
Croatian: Fibroza jetre na početku ispitivanja Bez fibroze, minimalna fibroza ili
English: BOTTLE LABEL (1-bottle pack)
Croatian: NALJEPNICA NA BOČICI (pakiranje s 1 bočicom)
English: Use in patients with advanced liver disease
Croatian: Bolesnici s transplantiranim organima